Paper: Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
Early data from a phase II trial of HMA-VEN for young adult patients with adverse-risk AML showed a very promising response rate 64.3% which compared favorably to a historical control of 38.3%. The numbers are still very small with plans to double the numbers as the trial continues to accrue. We know this subgroup has poor outcomes with conventional induction chemotherapy so it will be very interesting to see the longer f/u of this study. Importantly the early treatment related mortality was 0%. I am interested in seeing what percent of the CR patients end up receiving the planned HIDAC consolidation and allogenic transplant and the long term outcomes. Although HMA-VEN was initially designed as a continuous therapy, we are beginning to see promising data on its efficacy to get patients to a transplant.
